Sort
21,453 grants matching “tuberculosis”
SYNTHESIS OF INHIBITORS OF RHAMNOSE AND GALACTOSE METABOLISM
$148,800National Jewish Health · U19 · FY2000 · AI
EXPLOITATION OF NOVEL PATHWAYS FOR ANTITUBERCULOSIS AGENTS
$148,800National Jewish Health · U19 · FY2000 · AI
MURINE MODELS FOR EVALUATION OF NEW THERAPIES
$148,800National Jewish Health · U19 · FY2000 · AI
CORE--SYNTHESIS OF DRUGS AGAINST DORMANT AND SEMI-DORMANT BACILLI
$148,800National Jewish Health · U19 · FY2000 · AI
NEW THERAPIES IN MACROPHAGE AND IN VITRO MODELS
$148,800National Jewish Health · U19 · FY2000 · AI
Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease
$148,716Emily M. Henkle · Oregon Health & Science University · K01 · FY2022 · HL
Sex, HIV, and Air Pollution Effects on Post-TB Lung Disease (SHAPE PTLD)
$148,676Laurence Huang · University Of California, San Francisco · R01 · FY2025 · HL
TB PLEURISY &MONOCYTE TRANSMIGRATION IN AIDS
$148,674Indiana Univ-Purdue Univ At Indianapolis · R01 · FY2001 · AI
Investigating the acceptability and feasibility of home-based TB testing of household contacts using a new, mobile point-of-care technology
$148,645Andrew Medina-Marino · Foundation For Professional Development · R21 · FY2017 · EB
Interventions to reduce alcohol use and increase adherence to TB preventive therapy among HIV/TB co-infected drinkers (DIPT 1/2)
$148,569Judith Alissa Hahn · University Of California, San Francisco · U01 · FY2019 · AA
Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease
$148,545Emily M. Henkle · Oregon Health & Science University · K01 · FY2020 · HL
Host-Pathogen Interactions in a Failing Global lineage of MTBC:M.africanum
$148,518Souleymane Diallo · Univ Of Sciences, Tech & Tech Of Bamako · R01 · FY2015 · AI
Targetting the Niemann-Pick disease type C cellular pathway as a novel approach t
$148,502Frances Mary Platt · University Of Oxford · R21 · FY2012 · AI
IMMUNOLOGIC BASIS ENIVR MODULATION OF AUTOIM ARTHRITIS
$148,500University Of Maryland Baltimore · R21 · FY2001 · AI
Molecular characterization of M. marinum biofilms
$148,500University Of Minnesota Twin Cities · R21 · FY2004 · AI
IMMUNOLOGIC BASIS ENIVR MODULATION OF AUTOIM ARTHRITIS
$148,500University Of Maryland Baltimore · R21 · FY2000 · AI
Studies of Inherited Causes of Fungal Susceptability
$148,495Sergio Rosenzweig · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Innate Immunogenetics & Human Infections
$148,389Thomas R Hawn · University Of Washington · K24 · FY2014 · AI
Investigating the acceptability and feasibility of home-based TB testing of household contacts using a new, mobile point-of-care technology
$148,325Andrew Medina-Marino · Foundation For Professional Development · R21 · FY2016 · EB
Evidence of the burden of diabetes, gaps in the diabetes cascade-of-care and the impact of care and treatment on diabetes outcomes in HIV-positive and HIV-negative patients in South Africa
$148,200Alana Teresa Brennan · Boston University Medical Campus · K01 · FY2019 · DK
FUNCTION OF CD8T CELLS IN TUBERCULOSIS
$148,163University Of Pittsburgh At Pittsburgh · R01 · FY2001 · AI
VTEU: Phase I Clinical Trial to Evaluate Tuberculosis Therapeutics
$148,147Patricia Winokur · University Of Iowa · N01 · FY2016 · AI
Mycobacterial disease prevention: pharmacovigilance and inflammatory disease
$148,127Kevin Loring Winthrop · Oregon Health & Science University · K08 · FY2009 · HS
Mycobacterial disease prevention: pharmacovigilance and inflammatory disease
$148,127Kevin Loring Winthrop · Oregon Health & Science University · K08 · FY2010 · HS
Mycobacterial disease prevention: pharmacovigilance and inflammatory disease
$148,127Kevin Loring Winthrop · Oregon Health & Science University · K08 · FY2008 · HS